Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.
Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.